Brief: Vectivbio Announces Completion Of Enrollment For Colon-In-Continuity Cohort Of Stars Pivotal Phase 3 Study Investigating Apraglutide In Short Bowel Syndrome With Intestinal Failure
03/11/2022 11:49
Nov 3 (Reuters) - VectivBio Holding AG VECT.O :
* VECTIVBIO ANNOUNCES COMPLETION OF ENROLLMENT FOR
COLON-IN-CONTINUITY (CIC) COHORT OF STARS PIVOTAL PHASE 3 STUDY
INVESTIGATING APRAGLUTIDE IN SHORT BOWEL SYNDROME WITH
INTESTINAL FAILURE (SBS-IF)
* VECTIVBIO HOLDING AG - TOP-LINE PHASE 3 RESULTS EXPECTED
AT END
OF 2023
Source text for Eikon: ID:nGNX2Jp40K
Further company coverage: VECT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on VectivBio Holding AG
See all newsBrief: Ironwood And VectivBio Announce Expiration Of Hart-Scott-Rodino Waiting Period For Proposed Acquisition Of VectivBio
Brief: Ironwood Pharmaceuticals Says If Deal Aborts, VectivBio To Pay Termination Fee
U.S. STOCKS ON THE MOVE-Pfizer, Zoom Video, American Airlines
U.S. STOCKS ON THE MOVE-Atea Pharma, Microbot Medical, Krystal
U.S. STOCKS ON THE MOVE-NuScale Power Corp, Foot Locker, Greenhill